Wells Fargo’s Grace Therapeutics GRCE Stock Holding History

Wells Fargo’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.09K	Hold	1,800	–	–	﹤0.01%	6253
2026 Q1	$8.33K	Buy	+1,800	New	+$7.07K	﹤0.01%	6003
2020 Q1	–	Sell	-281	Closed	-$33K	–	6931
2019 Q4	$33K	Buy	+281	New	+$27.8K	﹤0.01%	5631
2019 Q3	–	Sell	-21	Closed	-$1K	–	6792
2019 Q2	$1K	Buy	+21	New	+$922	﹤0.01%	6299
2018 Q2	–	Sell	-180	Closed	-$9K	–	6627
2018 Q1	$9K	Hold	180	–	–	﹤0.01%	5975
2017 Q4	$8K	Buy	+180	New	+$12.1K	﹤0.01%	5978

Other funds holding GRCE

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Wells Fargo's GRCE Position: Q2 2026 in Review

Wells Fargo held its Grace Therapeutics (GRCE) position steady in Q2 2026 at 1,800 shares worth $4.09K. The position accounts for ﹤0.01% of the portfolio, ranked #6253.

Wells Fargo first reported a position in GRCE in Q4 2017 and has held it in 6 quarters since. The position peaked at $33K in Q4 2019. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

Wells Fargo held 1,800 shares of Grace Therapeutics worth $4.09K as of Q2 2026.
Wells Fargo left its Grace Therapeutics share count unchanged in Q2 2026.
Grace Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6253 holding.
Wells Fargo first reported a position in Grace Therapeutics in Q4 2017 and has held it in 6 quarters since.
Wells Fargo's Grace Therapeutics position peaked at $33K in Q4 2019.
33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.